37.2% required additional antibiotic therapy for secondary bacterial infection, and only one patient received the antiviral medication, Oseltamivir, due to coinfection with influenza A. One patient studied was admitted to the intensive care unit, required additional management with dexamethasone, IVIG, tocilizumab, granulocyte colony stimulating factor (G-CSF), platelet and blood transfusions, and invasive respiratory support. This evidence concerns the gene CSF3 and bacterial infectious disease.